PE20001333A1 - Proceso para estabilizar macrolidos de polieno - Google Patents

Proceso para estabilizar macrolidos de polieno

Info

Publication number
PE20001333A1
PE20001333A1 PE1999001209A PE00120999A PE20001333A1 PE 20001333 A1 PE20001333 A1 PE 20001333A1 PE 1999001209 A PE1999001209 A PE 1999001209A PE 00120999 A PE00120999 A PE 00120999A PE 20001333 A1 PE20001333 A1 PE 20001333A1
Authority
PE
Peru
Prior art keywords
stabilize
rapamycin
hydroxy
ethyl
refers
Prior art date
Application number
PE1999001209A
Other languages
English (en)
Inventor
Francois Navarro
Guy Stone
Samuel Petit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001333A1 publication Critical patent/PE20001333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO PARA ESTABILIZAR UN MACROLIDO DE POLIENO TAL COMO RAPAMICINA, 40-O-(2-HIDROXI)-ETIL-RAPAMICINA QUE COMPRENDE: AGREGAR UN ANTIOXIDANTE UTILIZANDOSE HASTA EL 1%, SIENDO 2,6-DIBUTILO TERCIARIO-4-METILFENOL AL MACROLIDO PURIFICADO. TAMBIEN SE REFIERE A UNA MEZCLA SOLIDA DE MACROLIDO DE POLIENO Y UN ANTIOXIDANTE Y A LA FORMA CRISTALINA DE 40-O-(2-HIDROXI)ETIL-RAPAMICINA QUE SE CARACTERIZA POR SU CELOSIA DE CRISTAL. TAMBIEN SE REFIERE A UN PROCESO PARA PURIFICAR 40-O-(2-HIDROXI)ETIL-RAPAMICINA
PE1999001209A 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno PE20001333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE20001333A1 true PE20001333A1 (es) 2000-12-12

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001209A PE20001333A1 (es) 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP1137439B2 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1876657B (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2651609A1 (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ302210B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU230174B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY120594A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL196627B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK286688B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI270550B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
JP4261365B2 (ja) 2002-02-13 2009-04-30 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 生物学的物質からのマクロライドの抽出方法
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
US7232486B2 (en) 2003-03-31 2007-06-19 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
DK1558622T3 (da) 2003-07-24 2008-02-25 Teva Gyogyszergyar Zartkoeruee Fremgangsmåde til oprensning af macrolider
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
KR20060126701A (ko) * 2003-12-10 2006-12-08 애크럭스 디디에스 피티와이 리미티드 경피 또는 국소 약물 전달에 따른 원치않는 효과의치료방법
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
AU2005292339A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
EP1957964A2 (en) * 2005-12-07 2008-08-20 Wyeth Pharmaceuticals Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
PE20071067A1 (es) * 2005-12-20 2007-11-26 Wyeth Corp Composiciones de rapamicina y cci-779 y metodo para su preparacion
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
CN103025753A (zh) * 2010-06-07 2013-04-03 泰立克公司 晶体盐酸依泽替米贝非溶剂化物
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (en) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprizing rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
WO2021194772A1 (en) * 2020-03-27 2021-09-30 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
ATE321053T1 (de) 1992-10-13 2006-04-15 Wyeth Corp Carbamate von rapamycin
CA2219659C (en) 1995-06-09 2008-03-18 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
CA2351580C (en) 2012-03-20
MY127579A (en) 2006-12-29
SI1137439T1 (sl) 2008-06-30
US20050107418A1 (en) 2005-05-19
US20080161334A1 (en) 2008-07-03
AR048073A2 (es) 2006-03-29
CN1876657A (zh) 2006-12-13
DE69936352T2 (de) 2008-02-14
CA2651609A1 (en) 2000-06-15
GB9826882D0 (en) 1999-01-27
AU759219B2 (en) 2003-04-10
RU2243769C2 (ru) 2005-01-10
US20090270441A1 (en) 2009-10-29
US20020032213A1 (en) 2002-03-14
AR054444A2 (es) 2007-06-27
ID29250A (id) 2001-08-16
HU230174B1 (hu) 2015-09-28
KR20060096477A (ko) 2006-09-11
NZ511936A (en) 2003-10-31
CN1374872A (zh) 2002-10-16
SI1137439T2 (sl) 2012-05-31
JP2002531527A (ja) 2002-09-24
EP1137439A2 (en) 2001-10-04
FR2786771A1 (fr) 2000-06-09
EP1743657A2 (en) 2007-01-17
TW200540179A (en) 2005-12-16
PL196627B1 (pl) 2008-01-31
NO332698B1 (no) 2012-12-10
PL348333A1 (en) 2002-05-20
HK1038889A1 (en) 2002-04-04
PT1137439E (pt) 2007-09-25
BR9915986A (pt) 2001-09-04
CN1261163C (zh) 2006-06-28
EP2279751A3 (en) 2011-02-16
CA2732620A1 (en) 2000-06-15
EP2269651A3 (en) 2011-03-09
CA2351580A1 (en) 2000-06-15
NO20012424L (no) 2001-05-16
DK1137439T4 (da) 2012-03-19
SK7662001A3 (en) 2001-12-03
ITMI992520A1 (it) 2001-06-02
ZA200104360B (en) 2002-01-16
IL143092A0 (en) 2002-04-21
US6605613B2 (en) 2003-08-12
PL208854B1 (pl) 2011-06-30
TR200101416T2 (tr) 2002-01-21
ITMI992520A0 (it) 1999-12-02
HK1038889B (zh) 2008-01-25
US7572804B2 (en) 2009-08-11
JP2005200429A (ja) 2005-07-28
JP2006111637A (ja) 2006-04-27
GB9904934D0 (en) 1999-04-28
CZ303006B6 (cs) 2012-02-22
WO2000033878A3 (en) 2000-11-02
NO20121113L (no) 2001-05-16
US7297703B2 (en) 2007-11-20
ATE365051T1 (de) 2007-07-15
DE69936352T3 (de) 2012-05-03
HU228939B1 (en) 2013-07-29
CO4980847A1 (es) 2000-11-27
NO20012424D0 (no) 2001-05-16
NZ527781A (en) 2004-11-26
NO334612B1 (no) 2014-04-22
HUP0104489A3 (en) 2004-05-28
MY120594A (en) 2005-11-30
AU1657300A (en) 2000-06-26
SG151072A1 (en) 2009-06-29
JP5165199B2 (ja) 2013-03-21
TWI270550B (en) 2007-01-11
CZ20012001A3 (cs) 2001-09-12
US7741338B2 (en) 2010-06-22
IT1319701B1 (it) 2003-10-27
ES2288033T5 (es) 2012-04-10
EP1743657A3 (en) 2007-03-28
EP2279751A2 (en) 2011-02-02
TR200201428T2 (tr) 2002-12-23
US20030191148A1 (en) 2003-10-09
SK287325B6 (sk) 2010-07-07
SK286688B6 (sk) 2009-03-05
BE1012869A3 (fr) 2001-04-03
WO2000033878A2 (en) 2000-06-15
DE69936352D1 (de) 2007-08-02
CZ302210B6 (cs) 2010-12-22
US6852729B2 (en) 2005-02-08
HUP0104489A2 (hu) 2002-03-28
EP2269651A2 (en) 2011-01-05
KR100695834B1 (ko) 2007-03-19
EP1137439B1 (en) 2007-06-20
EP1137439B2 (en) 2011-11-23
CA2732620C (en) 2013-08-06
AR026102A1 (es) 2003-01-29
JP5043308B2 (ja) 2012-10-10
KR20010101128A (ko) 2001-11-14
TWI248938B (en) 2006-02-11
CN1876657B (zh) 2013-01-09
FR2786771B1 (fr) 2002-12-27
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
JP3805625B2 (ja) 2006-08-02
ES2288033T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
PE20001333A1 (es) Proceso para estabilizar macrolidos de polieno
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
AR039667A2 (es) Procedimiento para la preparacion de la forma ii de 6-o-metileritromicina al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para preparar la forma ii de 6-o-metileritromicina a y otros derivados
PT915898E (pt) Forma i cristalina de claritromicina
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
CY1113383T1 (el) Μεθοδος για την παρασκευη (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
PE20050355A1 (es) Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20070318A1 (es) Metodo para purificar tigeciclina
BRPI0410705A (pt) forma cristalina de agonista de receptor 2 adrenérgico
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR023071A1 (es) Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
CR10095A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
EA200200819A1 (ru) Кристаллическая форма ii линезолида
AR057291A1 (es) Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis
SI1572699T1 (sl) Kristalne soli cefdinira
BR0308567A (pt) derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term